CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing RTP-026, a drug designed to reduce inflammation caused by heart attacks, thereby minimizing heart damage and the risk of heart failure. The project aims to validate the drug's effectiveness through clinical studies.
Ischemic Heart Disease kills more than 1.7M people/year in the EU, the vast majority via a heart attack (Myocardial Infarction - MI).
Heart failure (HF) is the major cause of death after MI with a prevalence of >26M individuals globally.
While current treatment involving restoration of blood flow to the heart saves the MI patients life it also causes additional damage to the heart through an inflammatory reaction (reperfusion injury).
ResoThers leading drug candidate, RTP-026, is an immunomodula…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 keywords.
